Connecticut’s comptroller explains his thinking about GLP-1s for state employees
In this OpEd for STAT, Comptroller Scanlon discusses the challenges his office faced in covering GLP-1s and other anti-obesity medications and why they selected Intellihealth
Amgen Enters Anti-Obesity Drug RaceWith early data and a possible advantage, Amgen enters the obesity drug race Amgen Enters Anti-Obesity Drug Race
A “14.5% total body weight loss certainly looks promising!” Katherine Saunders, an obesity specialist and founder of the obesity-focused telehealth company Intellihealth, wrote in an
